- Home
- NSTS vs ELUT Comparison
NSTS vs ELUT Comparison
Compare NSTS & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- ELUT
- Stock Information
- Founded
- NSTS 1921
- ELUT 2015
- Country
- NSTS United States
- ELUT United States
- Employees
- NSTS N/A
- ELUT N/A
- Industry
- NSTS Savings Institutions
- ELUT Medical Specialities
- Sector
- NSTS Finance
- ELUT Health Care
- Exchange
- NSTS Nasdaq
- ELUT Nasdaq
- Market Cap
- NSTS 65.5M
- ELUT 73.2M
- IPO Year
- NSTS N/A
- ELUT 2020
- Fundamental
- Price
- NSTS $12.40
- ELUT $1.81
- Analyst Decision
- NSTS
- ELUT Strong Buy
- Analyst Count
- NSTS 0
- ELUT 2
- Target Price
- NSTS N/A
- ELUT $8.00
- AVG Volume (30 Days)
- NSTS 6.6K
- ELUT 25.1K
- Earning Date
- NSTS 08-08-2025
- ELUT 08-06-2025
- Dividend Yield
- NSTS N/A
- ELUT N/A
- EPS Growth
- NSTS N/A
- ELUT N/A
- EPS
- NSTS N/A
- ELUT N/A
- Revenue
- NSTS $9,115,000.00
- ELUT $23,711,000.00
- Revenue This Year
- NSTS N/A
- ELUT $20.10
- Revenue Next Year
- NSTS N/A
- ELUT $85.89
- P/E Ratio
- NSTS N/A
- ELUT N/A
- Revenue Growth
- NSTS 78.72
- ELUT N/A
- 52 Week Low
- NSTS $9.37
- ELUT $1.61
- 52 Week High
- NSTS $13.32
- ELUT $5.24
- Technical
- Relative Strength Index (RSI)
- NSTS 61.75
- ELUT 45.88
- Support Level
- NSTS $12.32
- ELUT $1.72
- Resistance Level
- NSTS $12.40
- ELUT $1.96
- Average True Range (ATR)
- NSTS 0.07
- ELUT 0.15
- MACD
- NSTS -0.03
- ELUT 0.01
- Stochastic Oscillator
- NSTS 47.37
- ELUT 24.13
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.